MICHAEL SØNDERGAARD GRAFISK DESIGN

LOGO MED ORIGINAL
TM-STØRRELSE
LOGO MED
LIDT STØRRE TM
CEL Program
DTU BUSINESS
Master in Management of Technology – MMT
An International
Executive MBA Programme
Focusing on innovation,
business development and
personal leadership
DTU Business
DTU Executive School of Business
Bærbare sandwich-skilte
Til 2 bærere ... altså 4 print.
Print på
både maveog
rygsiden
CEL TM Program
The product development process of the
pharmaceutical industry is unique as all new
drug developments undergo a strict approval
process following a series of clinical trials
before a new drug can be approved to the
market.
The clinical trial phases are defined by intensive
human testing of new products, which
have duration of 8 years in average (DiMasi
2001). Only one in five products are eventually
approved for the market and therefore
survive all phases of clinical trials (DiMasi and
Grabowski 2007). Estimations of the cost of
going through all phases of clinical trials are
Neo Sans Bold
Neo Sans Bold
Helvetica Black
trademark symbol
med bogstaverne TM
SUB IDENTITY | PRODUCT IDENTITY | WEB DESIGN | PR MATERIALE
i som oprykkede tegn
(superscript)
PROJECT:
The InnoCommunity
Project. The project title
can be upto 3 lines
Explaining the survival rate of new pharmaceutical products in
clinical trials. The header can be 2 lines
between $ 600 – 900 Million, which amount
to approximate 70 % of the overall R&D expenses
of developing a new drug (Grabowski,
2003; DiMasi ét al. 2003, PhRMA).
With such a significant ratio of R%D expenses
spend on the clinical trial phases a better
understanding of this process is needed. A
central focus of this study is the dependence
on external resources in the approval process
as the clinical trials are conducted at hospitals
and medical centers. The hypothesis of this
study is therefore, that the company network
of hospital relations has a high influence on
the approval process and end result here
FUNDI